Compare RVTY & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVTY | NBIX |
|---|---|---|
| Founded | 1937 | 1992 |
| Country | United States | United States |
| Employees | 11000 | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 13.2B |
| IPO Year | 1994 | 1996 |
| Metric | RVTY | NBIX |
|---|---|---|
| Price | $102.15 | $162.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 16 | 22 |
| Target Price | $109.67 | ★ $180.91 |
| AVG Volume (30 Days) | ★ 1.3M | 1.1M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.34% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | 0.36 | ★ 1.91 |
| Revenue | ★ $3,311,822,000.00 | $161,626,000.00 |
| Revenue This Year | $6.37 | $24.73 |
| Revenue Next Year | $5.10 | $13.14 |
| P/E Ratio | $289.25 | ★ $86.51 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $81.22 | $122.14 |
| 52 Week High | $118.30 | $169.57 |
| Indicator | RVTY | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 58.26 | 60.69 |
| Support Level | $94.04 | $153.30 |
| Resistance Level | $102.68 | N/A |
| Average True Range (ATR) | 3.58 | 4.86 |
| MACD | 0.14 | -0.27 |
| Stochastic Oscillator | 71.63 | 58.02 |
Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.